All Stories

  1. OA10 Using single-cell technology to understand the cellular landscape of colonic disease in systemic sclerosis
  2. Associations between demographic, clinical and dietary factors and flares in inflammatory bowel disease: the PRognostic effect of Environmental factors in Crohn’s and Colitis (PREdiCCt) prospective cohort study
  3. P1120 Impact of Implementing a Pharmacist-Led Selective JAK1 Inhibitor Clinic on IBD Care: A Retrospective Pre-Post Study
  4. Clinical utility of pre-treatment four-digit-resolution HLA genotyping to guide anti-tumor necrosis factor choice and concomitant immunomodulator use
  5. Delivering a Modified Mindfulness Based Stress Reduction Intervention for Inflammatory Bowel Disease in Adolescents and Young Adults: Assessing Feasibility, Acceptability, and Effectiveness
  6. Zenker peroral endoscopic myotomy (Z-POEM) is safe and effective for the management of pharyngeal pouch: a multicentre retrospective cohort study
  7. P170 Zenker peroral endoscopic myotomy (Z-POEM) is a safe and feasible alternative first-line treatment for zenker’s diverticulum
  8. ABS0165 PROVISIONAL EXPERT RECOMMENDATIONS FOR THE MANAGEMENT OF FECAL INCONTINENCE IN SYSTEMIC SCLEROSIS: A REPORT FROM WORLD SCLERODERMA FOUNDATION (WSF) GASTROINTESTINAL “AD HOC COMMITTEE”
  9. OP0121 PROVISIONAL EXPERT RECOMMENDATIONS FOR THE MANAGEMENT OF REFRACTORY GASTROESOPHAGEAL REFLUX DISEASE IN SYSTEMIC SCLEROSIS: A REPORT FROM THE WORLD SCLERODERMA FOUNDATION (WSF) GASTROINTESTINAL “AD HOC COMMITTEE”
  10. Endoscopic Suturing for Defect Closure in the Upper Gastrointestinal Tract: A Retrospective Cohort Study
  11. Targeted screening of at-risk patients with chronic heartburn using a non-endoscopic capsule sponge device can enhance the detection of Barrett’s oesophagus
  12. Oesophageal pH testing: everything you wanted to know but were too afraid to ask
  13. Systemic sclerosis–related fecal incontinence: a scoping review focusing on a neglected manifestation
  14. A multimodal endoscopic approach for esophageal fistula closure
  15. The A to Z of Peroral Endoscopic Myotomy
  16. S1537 Radiofrequency Vapor Ablation is Safe and Well-Tolerated for Duodenal Mucosal Ablation in the Treatment of Type 2 Diabetes: Six Month Results From the First-in-Human Dose Finding Study
  17. Cough and gastro-esophageal reflux in systemic sclerosis-associated ILD:a prospective study
  18. The safety and efficacy of endoscopic approaches for the management of Zenker’s diverticulum: a multicentre retrospective study
  19. A disease-associated gene desert directs macrophage inflammation through ETS2
  20. Endoscopic suturing and clipping devices for defects in the GI tract
  21. P172 A comparison of the safety and efficacy of flexible versus rigid endoscopic approaches for the management of zenker’s diverticulum
  22. P223 Evaluation of the safety and efficacy of transoral incisionless fundoplication (TIF2.0) for gastro-oesophageal reflux disease: a UK cohort study
  23. P262 Performance of endoscopic approaches for the treatment of Zenker’s diverticulum: a systematic review and meta-analysis
  24. P272 Safety and efficacy of cryoablation for the treatment of Barrett’s oesophagus: a systematic review and meta-analysis
  25. P152 Safety and efficacy of endoscopic vacuum therapy for the management of leaks following bariatric surgery: a systematic review and meta-analysis
  26. P221 Zenker per-oral endoscopic myotomy (Z-POEM) is safe and effective for the management of pharyngeal pouch
  27. A MULTICENTRE RETROSPECTIVE COHORT STUDY TO COMPARE THE SAFETY AND EFFICACY OF ZENKER PER-ORAL ENDOSCOPIC MYOTOMY, FLEXIBLE DIVERTICULOTOMY, AND RIGID DIVERTICULOTOMY FOR THE MANAGEMENT OF ZENKER’S DIVERTICULUM
  28. A MULTICENTRE RETROSPECTIVE COHORT STUDY TO COMPARE THE SAFETY AND EFFICACY OF ZENKER PER-ORAL ENDOSCOPIC MYOTOMY, FLEXIBLE DIVERTICULOTOMY, AND RIGID DIVERTICULOTOMY FOR THE MANAGEMENT OF ZENKER’S DIVERTICULUM
  29. PERFORMANCE OF ENDOSCOPIC APPROACHES FOR ZENKER DIVERTICULUM MANAGEMENT: A SYSTEMATIC REVIEW AND META-ANALYSIS
  30. PERFORMANCE OF ENDOSCOPIC APPROACHES FOR ZENKER DIVERTICULUM MANAGEMENT: A SYSTEMATIC REVIEW AND META-ANALYSIS
  31. SAFETY AND EFFICACY OF CRYO-ABLATION ON BARRETT ESOPHAGUS: A SYSTEMATIC REVIEW AND META-ANALYSIS
  32. SAFETY AND EFFICACY OF CRYO-ABLATION ON BARRETT ESOPHAGUS: A SYSTEMATIC REVIEW AND META-ANALYSIS
  33. THE UK EXPERIENCE OF ZENKER PER-ORAL ENDOSCOPIC MYOTOMY (Z-POEM) FOR THE TREATMENT OF ZENKER’S DIVERTICULUM
  34. THE UK EXPERIENCE OF ZENKER PER-ORAL ENDOSCOPIC MYOTOMY (Z-POEM) FOR THE TREATMENT OF ZENKER’S DIVERTICULUM
  35. A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial
  36. Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study
  37. P135 Association of Serum Anti-Muscarinic 3 Antibodies with Gastrointestinal Disease in Systemic Sclerosis
  38. A multicentre retrospective cohort study to compare the safety and efficacy of zenker per-oral endoscopic myotomy, flexible diverticulotomy, and rigid diverticulotomy for the management of zenker’s diverticulum
  39. Endoscopic suturing for defect closure in the upper gastrointestinal tract: a retrospective cohort study
  40. Performance of endoscopic approaches for Zenker diverticulum management: a systematic review and meta-analysis
  41. Safety and efficacy of cryo-ablation on Barrett esophagus: a systematic review and meta-analysis
  42. The UK experience of zenker per-oral endoscopic myotomy (z-poem) for the treatment of zenker’s diverticulum
  43. The safety and efficacy of endoscopic vacuum therapy for the management of leaks following bariatric surgery: A systematic review and meta-analysis
  44. Role of oesophageal balloon cryoablation in combination with personalised immunotherapy to achieve luminal control in metastatic oesophageal cancer: a case report
  45. The endoscopic management of oesophageal strictures
  46. Metabolic Endoscopy: Should Gastroenterologists Be Treating Type 2 Diabetes?
  47. Peroral endoscopic myotomy for the management of symptomatic cricopharyngeal bar (C-POEM): a case series and video demonstration
  48. Biologic Therapy for Inflammatory Bowel Disease: Real-World Comparative Effectiveness and Impact of Drug Sequencing in 13 222 Patients within the UK IBD BioResource
  49. Baseline Expression of Immune Gene Modules in Blood is Associated With Primary Response to Anti-TNF Therapy in Crohn’s Disease Patients
  50. Symptomatic duodenal metastasis from a small cell lung cancer primary: a rare case
  51. Metabolic and Bariatric Endoscopy: A Mini-Review
  52. Management of a large percutaneous endoscopic gastrostomy tube-associated gastric ulcer with endoscopic suturing
  53. Safety, Effectiveness, and Treatment Persistence of Subcutaneous Vedolizumab in IBD: A Multicenter Study From the United Kingdom
  54. Anti-TNF Biologicals Enhance the Anti-Inflammatory Properties of IgG N-Glycome in Crohn’s Disease
  55. A disease-associated gene desert orchestrates macrophage inflammatory responses via ETS2
  56. Phenome-Wide Association Study of Drugs and Co-morbidities Associated with Gastrointestinal Dysfunction in Systemic Sclerosis
  57. Genome-Wide Methylation Profiling in 229 Patients With Crohn’s Disease Requiring Intestinal Resection: Epigenetic Analysis of the Trial of Prevention of Post-operative Crohn’s Disease (TOPPIC)
  58. Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a pr...
  59. Between progress and changing times: The journey of UEG Education Committee's chair
  60. Treatment adaptations and outcomes of patients experiencing inflammatory bowel disease flares during the early COVID ‐19 pandemic: the PREPARE‐IBD multicentre cohort study
  61. Blood and guts
  62. Proton pump inhibitors in systemic sclerosis: a reappraisal to optimise treatment of gastro-oesophageal reflux disease
  63. Diagnostic Performance of Magnetic Resonance Enterography Disease Activity Indices Compared with a Histological Reference Standard for Adult Terminal Ileal Crohn’s Disease: Experience from the METRIC Trial
  64. Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab
  65. Comparative effectiveness of a second-line biologic in patients with ulcerative colitis: vedolizumab followed by an anti-TNF versus anti-TNF followed by vedolizumab
  66. Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in infliximab- and vedolizumab-treated patients
  67. The Relationship Between Mucosal Microbiota, Colitis, and Systemic Inflammation in Chronic Granulomatous Disorder
  68. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial
  69. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study
  70. PMO-29 Switching between infliximab biosimilars: experience from two inflammatory bowel disease centres
  71. PMO-33 Infliximab biosimilar switching – can you switch more than once?
  72. PMO-50 Factors independently associated with fatigue in IBD: results from the PREdiCCt study
  73. Benefits of Structured Pediatric to Adult Transition in Inflammatory Bowel Disease
  74. Covid-19 vaccine-induced antibodies are attenuated and decay rapidly in infliximab treated patients
  75. The relationship between mucosal microbiota, colitis and systemic inflammation in Chronic Granulomatous Disorder
  76. Autoantibody predictors of gastrointestinal symptoms in systemic sclerosis
  77. Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab
  78. Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control study
  79. Endoscopy during the peak of COVID-19 pandemic: impact on activity and financial implications for a tertiary referral center in London
  80. Editorial: fatigue—difficult to assess and difficult to treat
  81. Constipation, Bloating and Abdominal Pain
  82. Thiopurine monotherapy is effective in ulcerative colitis but significantly less so in Crohn’s disease: long-term outcomes for 11 928 patients in the UK inflammatory bowel disease bioresource
  83. UEG Guidelines framework to guide clinical practice
  84. Organisational changes and challenges for inflammatory bowel disease services in the UK during the COVID-19 pandemic
  85. Adaptations to the British Society of Gastroenterology guidelines on the management of acute severe UC in the context of the COVID-19 pandemic: a RAND appropriateness panel
  86. British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic
  87. P156 Understanding the associations and impact of severe gastrointestinal involvement in systemic sclerosis: a structured approach
  88. The cost-effectiveness of radiofrequency ablation for treating patients with gastric antral vascular ectasia refractory to first line endoscopic therapy
  89. UEG Education—building on success
  90. HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn’s Disease
  91. P738 Real world outcomes on the efficacy and safety of combination of biologic and immunosuppressive therapy in liver transplant recipients with inflammatory bowel disease
  92. Diagnosis and management of bile acid diarrhoea: a survey of UK expert opinion and practice
  93. Magnetic resonance enterography compared with ultrasonography in newly diagnosed and relapsing Crohn’s disease patients: the METRIC diagnostic accuracy study
  94. IBD BioResource: an open-access platform of 25 000 patients to accelerate research in Crohn’s and Colitis
  95. Chronic Granulomatous Disorder–Associated Colitis Can Be Accurately Evaluated with MRI Scans and Fecal Calprotectin Level
  96. PTH-039 The cost-effectiveness of radiofrequency ablation for gastric antral vascular ectasia refractory to first-line endoscopic therapy
  97. Editorial: combination immunosuppressive therapy to treat Crohn’s disease - ready for all age groups?
  98. Radiological findings in gastrointestinal scleroderma
  99. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study
  100. Cause or effect? Interpreting emerging evidence for dysbiosis in systemic sclerosis
  101. Association of Genetic Variants in NUDT15 With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease
  102. Radiofrequency ablation for patients with refractory symptomatic anaemia secondary to gastric antral vascular ectasia
  103. In memory of Dr Tomer Adar
  104. A New Look at Familial Risk of Inflammatory Bowel Disease in the Ashkenazi Jewish Population
  105. Rare coding variant analysis in a large cohort of Ashkenazi Jewish families with inflammatory bowel disease
  106. Magnetic resonance enterography, small bowel ultrasound and colonoscopy to diagnose and stage Crohn’s disease: patient acceptability and perceived burden
  107. Diagnostic accuracy of magnetic resonance enterography and small bowel ultrasound for the extent and activity of newly diagnosed and relapsed Crohn's disease (METRIC): a multicentre trial
  108. 118 ENDOSCOPIC RADIOFREQUENCY ABLATION IS AN EFFECTIVE THERAPY IN PATIENTS WITH SYMPTOMATIC ANAEMIA SECONDARY TO GASTRIC ANTRAL VASCULAR ECTASIA
  109. A Randomized, Double-blind, Placebo-controlled, Parallel-group, Pilot Study of Cannabidiol-rich Botanical Extract in the Symptomatic Treatment of Ulcerative Colitis
  110. Editorial: anti-TNF therapy and myopenia in Crohn's disease-another step towards personalised medicine
  111. There is a need for new systemic sclerosis subset criteria. A content analytic approach
  112. PTH-041 Definitive management of a very rare cause of significant acute upper gastrointestinal bleeding: gastric lipoma resected by hybrid endoscopic submucosal dissection
  113. PTH-054 Endoscopic submucosal dissection (esd) of gastric and rectal neuroendocrine tumours (nets): a case series from a tertiary referral centre (with video)
  114. AODTU-001 Radiofrequency ablation in patients with symptomatic anaemia secondary to gastric antral vascular ectasia
  115. Structured Transition Enhances Clinical Outcome without an Increase in Healthcare Cost in Adolescent Patients with IBD: the UK Transit Study
  116. The Impact of Transition to Adult Gastroenterology Services on Health-Related Quality of Life in Young Adult Patients with IBD: The UK Transit Study
  117. UK guideline on transition of adolescent and young persons with chronic digestive diseases from paediatric to adult care
  118. P363 The impact of transition to adult gastroenterology services on health-related quality of life in young adult patients with IBD: the UK TRANSIT study
  119. P543 Structured transition enhances clinical outcome without an increase in healthcare cost in adolescent patients with IBD: the UK TRANSIT study
  120. Small bowel obstruction caused by a migrated Obalon gastric bariatric balloon: nonsurgical management by antegrade double-balloon panenteroscopy
  121. Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): a multicentre, double-blind, randomised controlled trial
  122. The role of dietary supplements in inflammatory bowel disease
  123. Small and Large Intestinal Involvement and Nutritional Issues
  124. Gallstone mimicry: a rare cause of abdominal pain
  125. Gastrointestinal manifestations of systemic sclerosis
  126. The ABC of E-learning: Utilizing E-learning resources for training and research in gastroenterology
  127. Elevated liver enzymes in inflammatory bowel disease
  128. Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta-analysis
  129. P.14.3 CORRELATION BETWEEN CLINICAL RESPONSE AND ANEMIA RESOLUTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES TREATED WITH ANTI-TNF INHIBITORS
  130. Endoscopic resection of a giant ileal inflammatory fibroid polyp by retrograde double-balloon enteroscopy
  131. Clinical Features and HLA Association of 5-Aminosalicylate (5-ASA)-induced Nephrotoxicity in Inflammatory Bowel Disease
  132. P32 Role of non acid and proximal reflux in scleroderma-associated interstitial lung disease
  133. Impact of a decade of successful antiretroviral therapy initiated at HIV-1 seroconversion on blood and rectal reservoirs
  134. OP-16 DIETARY INTERVENTION USING THE LOW FODMAP DIET VERSUS THE “MILK, EGG, WHEAT AND SOYA FREE” DIET FOR TREATMENT OF FUNCTIONAL GUT DISORDERS A SINGLE CENTRE EXPERIENCE
  135. Gastro-oesophageal dismotility measurements in scleroderma-associated interstitial lung disease: Correlation with respiratory and reflux symptoms
  136. Sustained benefit from intravenous immunoglobulin therapy for gastrointestinal involvement in systemic sclerosis
  137. Intractable diarrhoea despite immune reconstitution in an HIV positive man
  138. UEG E‐learning: The future has arrived
  139. 8th IAS Conference on HIV Pathogenesis, Treatment & Prevention 19–22 July 2015, Vancouver, Canada
  140. Indurated plaques on the penis
  141. Gut symptoms in diabetics correlate with components of the rectoanal inhibitory reflex, but not with pudendal nerve motor latencies or systemic autonomic neuropathy
  142. PTH-056 Trial to assess cannabidiol in the symptomatic treatment of ulcerative colitis
  143. AB0727 There is a Need for New Systemic Sclerosis Subset Criteria. A Content Analytic Approach
  144. OC-055 ‘ibdpassport’: evaluating the quality of an internet-based travel resource for inflammatory bowel disease
  145. PTH-072 Diagnostic yield of mr enterography versus wireless video capsule endoscopy in suspected small bowel paediatric crohn’s disease
  146. Hepatic portal venous gas and portal venous thrombosis following colonoscopy in a patient with terminal ileal Crohn's disease
  147. Irritable bowel syndrome
  148. Travel health and pretravel preparation in the patient with inflammatory bowel disease
  149. Sa1264 A Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Centred Pilot Study to Assess the Symptomatic Treatment of Ulcerative Colitis With Cannabidiol
  150. Sa1127 Cutaneous Events During Anti-Tumour Necrosis Factor (Anti-TNF) Treatment at a London Inflammatory Bowel Disease (IBD) Centre
  151. Sa1373 Significant Findings From a Randomised Control Trial of Posterior Tibial Nerve Stimulation in Systemic Sclerosis Associated Faecal Incontinence
  152. Tu1079 ‘IBDpassport’: Evaluating the Quality of an Internet-Based Travel Resource for Inflammatory Bowel Disease
  153. Tu1080 A Single-Centre Pilot Study Examining Internet Use for Health-Related Information Among Patients With Inflammatory Bowel Disease
  154. A rare cause of abdominal pain, diarrhoea and GI bleeding
  155. UEG Education: time to shape the future
  156. P-057: A nurse-led tertiary adolescent IBD clinic: 12 month trial and exploration of patient satisfaction
  157. P-114: Response to exclusive enteral nutrition (EEN) in adolescent patients with newly diagnosed Crohn’s disease (CD)
  158. P-115: Thiopurine metabolite (TM) monitoring in adolescent IBD (aIBD): Poor adherence is common
  159. METRIC (MREnterography or ulTRasound in Crohn’s disease): a study protocol for a multicentre, non-randomised, single-arm, prospective comparison study of magnetic resonance enterography and small bowel ultrasound compared to a reference standard in tho...
  160. CMV in the gut: a critical review of CMV detection in the immunocompetent host with colitis
  161. OC-055 Ibd Passport-developing An Evidence-based Internet Travel Resource For Inflammatory Bowel Disease: A Report Of The Initial Stages Of Implementation
  162. PTU-092 Patient And Professionals Perceptions Of Travel Behaviour In Inflammatory Bowel Disease
  163. PWE-115 Patients Continue To Travel Abroad Despite Recently Active Disease And Travel Concerns: Results Of A Single Centre Study In Inflammatory Bowel Disease And Travel
  164. PWE-183 Preliminary Significant Findings From A Randomised Control Trial Of Posterior Tibial Nerve Stimulation In Systemic Sclerosis Associated Faecal Incontinence
  165. PTH-044 A Single-centre Pilot Study Examining Internet Use For Health Related Information Among Patients With Inflammatory Bowel Disease
  166. Mo2015 Preliminary Significant Findings From a Randomised Control Trial of Posterior Tibial Nerve Stimulation in Systemic Sclerosis Associated Faecal Incontinence
  167. Su1095 A Recent Flare of Disease Does Not Prohibit Travel: Early Results of a Single Centre Study in Inflammatory Bowel Disease and Travel
  168. Tu1275 Prevalence, Type, and Management of Anaemia in Patients Presenting With Congestive Cardiac Failure
  169. P574 A recent flare of disease does not prohibit travel: early results of a single centre study in inflammatory bowel disease and travel
  170. P553 A single-centre pilot study examining internet use for health related information among patients with inflammatory bowel disease
  171. Anti-tumour necrosis factor agent and liver injury: Literature review, recommendations for management
  172. Using an ‘action set’ for the management of acute upper gastrointestinal bleeding
  173. Bloody Diarrhoea
  174. Yield and cost effectiveness of mycobacterial infection detection using a simple IGRA-based protocol in UK subjects with inflammatory bowel disease suitable for anti-TNFα therapy
  175. PTH-132 Iron Deficiency Anaemia Nurse Led Clinic: Audit of 1st Year
  176. PTH-100 Psychological Morbidity and Provision of Psychological Support in the Inflammatory Bowel Disease Clinic
  177. PTH-112 Infliximab Promotes Steroid free Remission in Patients with Chronic Active Ulcerative Colitis– a UK Single Centre Experience
  178. PTH-113 Clinical Response to Induction Anti-Tnf Therapy has no Effect on Haemoglobin Levels in Patients with IBD
  179. PTH-114 Skin Pathology Associated with Anti-Tumour Necrosis Factor (ANTI-TNF) Therapy- a Single UK IBD Centre Experience
  180. P366 Skin pathology associated with anti-tumournecrosis factor (anti-TNF) therapy – a single UK IBD centre experience
  181. P57 Comparative Cost-Effectiveness of IGRA to Detect Latent TB Infection in UK Inflammatory Bowel Disease Patients Initiating Anti-TNFα Agents: Abstract P57 Table 1
  182. Weight loss and lumbosacral back pain in a 79-year-old Indian man
  183. Malignant mimicry—a 17-year-old with abdominal pain and weight loss
  184. PTU-113 Quality of life in patients with ileoanal pouch: a survey comparing two different patient populations
  185. PTU-096 The use of commercial interferon-γ release assays to screen for mycobacterial infection in inflammatory bowel disease patients initiating anti-TNF agents
  186. Do We Do Enough to Convince Our Patients With Crohn's Disease to Stop Smoking? Results From a North London Audit
  187. Influence of Smoking and Other Environmental Factors in Inflammatory Bowel Disease Activity: What Do Our Patients Think?
  188. Irritable bowel syndrome
  189. Tu1576 Capsule Endoscopy for Obscure Occult Gastrointestinal Bleeding: Incidence of Pathology Detected Within Reach of a Standard Gastroscope
  190. Influence of smoking and other environmental factors in inflammatory bowel disease activity: what do our patients think?
  191. Iron deficiency anaemia is common in patients with an ileoanal pouch and is not always associated with inflammation
  192. There will be blood... a complete audit cycle
  193. Images of the terminal ileum are more convincing than cecal images for verifying the extent of colonoscopy
  194. Attitudes and Experiences of Adolescents in an Innovative IBD Transition Service
  195. T1272 Screening Patients Initiating Anti-TNF Agents for Mycobacterial Infection Using Interferon-Gamma Release Assays (IGRA): the Experience of a Large Inflammatory Bowel Disease Service
  196. Amitriptyline modifies the visceral hypersensitivity response to acute stress in the irritable bowel syndrome
  197. The effect of Khat (Catha edulis) as an appetite suppressant is independent of ghrelin and PYY secretion
  198. Acid-related oesophageal sensitivity, not dysmotility, differentiates subgroups of patients with non-erosive reflux disease
  199. Gastrointestinal Manifestations of Systemic Sclerosis
  200. Pharmacological modulation of gut mucosal and large vessel blood flow
  201. Reaping value from intellectual property: DuPont's strategic approach achieves global growth
  202. Ghrelin augments afferent response to distension in rat isolated jejunum
  203. The effect of different macronutrient infusions on appetite, ghrelin and peptide YY in parenterally fed patients
  204. Diabetes and the Gastrointestinal System
  205. Prokineticin-2, motilin, ghrelin and metoclopramide: Prokinetic utility in mouse stomach and colon
  206. Ghrelin enhances gastric emptying in diabetic gastroparesis: a double blind, placebo controlled, crossover study
  207. Effect of acute physical and psychological stress on gut autonomic innervation in irritable bowel syndrome
  208. Sporadic duodenal adenoma is associated with colorectal neoplasia
  209. Ghrelin for the gastroenterologist: history and potential
  210. Biofeedback, not laxatives, improves symptoms, transit and autonomic tone in functional constipation
  211. Medical management of diverticular disease
  212. Colonic Disorders